000279490 001__ 279490
000279490 005__ 20250709100939.0
000279490 037__ $$aDZNE-2025-00817
000279490 1001_ $$0P:(DE-2719)2810938$$aMüller, Stephan A$$b0$$udzne
000279490 245__ $$aDataset: Plasma proteomics of mice treated with BACE inhibitors
000279490 260__ $$bPRoteomics IDEntifications Database$$c2024
000279490 3367_ $$2BibTeX$$aMISC
000279490 3367_ $$0PUB:(DE-HGF)32$$2PUB:(DE-HGF)$$aDataset$$bdataset$$mdataset$$s1752047288_8074
000279490 3367_ $$026$$2EndNote$$aChart or Table
000279490 3367_ $$2DataCite$$aDataset
000279490 3367_ $$2ORCID$$aDATA_SET
000279490 3367_ $$2DINI$$aResearchData
000279490 520__ $$aThe Beta-secretase BACE1 is a central drug target for Alzheimer’s disease. Clinically tested, BACE1-directed inhibitors also block the homologous protease BACE2. Yet, little is known about physiological BACE2 substrates and functions in vivo. To discover potential BAC2 substrates in plasma, mice were treated with a non-specific BACE inhibitor (Cpd89) and a BACE1 preferring inhibitor (LY2811376). Plasma proteomics using DIA showed a reduced abundance of soluble FLT4 (sVEGFR3) for the non-specific inhbtor but not for the BACE1 preferring inhibitor. Conclusively, sVEGFR3 is a potential marker for BACE2 inhibition in plasma.
000279490 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000279490 588__ $$aDataset connected to DataCite
000279490 7001_ $$0P:(DE-2719)2181459$$aLichtenthaler, Stefan$$b1$$udzne
000279490 7870_ $$0DZNE-2024-01041$$aSchmidt, Andree et.al.$$dAnn Arbor, Mich. : ASCJ, 2024$$iRelatedTo$$r$$tThe Alzheimer's disease-linked protease BACE2 cleaves VEGFR3 and modulates its signaling.
000279490 8564_ $$uhttps://wwwdev.ebi.ac.uk/pride/archive/projects/PXD042669
000279490 909CO $$ooai:pub.dzne.de:279490$$pVDB
000279490 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810938$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b0$$kDZNE
000279490 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2181459$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000279490 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000279490 9201_ $$0I:(DE-2719)1110006$$kAG Lichtenthaler$$lNeuroproteomics$$x0
000279490 980__ $$adataset
000279490 980__ $$aVDB
000279490 980__ $$aI:(DE-2719)1110006
000279490 980__ $$aUNRESTRICTED